LINKER-MM4NCT05828511
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 30 versions: 29 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 10 words
- Enrollment closed, study ongoing
- Enrollment target: estimated 149 to confirmed 148
- Site details revised at 32 of 32 sites
- Minor Site details revised at 1 of 32 sitesv29
- Minor Study sites revised (32)v28
- Notable Eligibility criteria expanded, about 5 words
- Enrollment target: 132 to 149
- Secondary endpoints revised (28)
- Primary endpoints revised (10)
- Minor Study sites: 30 to 32v26
Show 23 earlier versionsHide 23 earlier versions
- Minor Study sites revised (30)v25
- Minor Study sites revised (30)v23
- Minor Study sites: 29 to 30v22
- Minor Study sites: 28 to 29v21
- Minor Study sites revised (28)v20
- Minor Study sites: 27 to 28v19
- Minor Study sites: 26 to 27v18
- Minor Study sites: 22 to 26v17
- Minor Study sites: 19 to 22v16
- Minor Study sites: 18 to 19v15
- Minor Study sites: 15 to 18v14
- Minor Study sites: 11 to 15v13
- Minor Study sites: 10 to 11v12
- Minor Study sites: 9 to 10v11
- Minor Study sites: 8 to 9v10
- Minor Study sites: 5 to 8v9
Notable Eligibility criteria expanded, about 7 wordsv8 Show 4 more changesShow less
- Primary endpoints revised (10)
- Study sites: 4 to 5
- Secondary endpoints revised (28)
- Study title expanded, about 1 word
- Minor Study sites: 2 to 4v7
- Minor Study sites: 1 to 2
- Primary and study completion dates: Nov 30, 2035 to Nov 2, 2035
- Start date changed from estimate of Jan 12, 2024 to Dec 19, 2023
- Notable Start date: Dec 8, 2023 to Jan 12, 2024
- Primary and study completion dates: Oct 19, 2035 to Nov 30, 2035
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date: Nov 16, 2023 to Dec 8, 2023
- Minor Primary and study completion dates: Sep 30, 2035 to Oct 19, 2035
- Start date: Oct 27, 2023 to Nov 16, 2023
- Notable Start date: Jul 31, 2023 to Oct 27, 2023
- Primary and study completion dates: Jun 22, 2035 to Sep 30, 2035
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (28)
Show 23 moreShow less
Arms and interventions
Linvoseltamab dose escalation (part A), dose expansion (part B), and evaluation of alternative step-up regimen (part C) for participants with NDMM who are treatment-naïve.
Transplant-ineligible participants, enrolled in dose expansion, will receive selected linvoseltamab regimen until disease progression as per protocol.
Transplant-eligible participants, enrolled in dose expansion, will receive selected linvoseltamab regimen for a fixed duration of treatment as per protocol
Drugs: Linvoseltamab
Sites
32 sites in 3 countries
United States 13, Spain 11, France 8